Disease activity indices in psoriatic arthritis: current and evolving concepts
- PMID: 34003419
- DOI: 10.1007/s10067-021-05774-9
Disease activity indices in psoriatic arthritis: current and evolving concepts
Abstract
Psoriatic arthritis (PsA) is a highly heterogenous disease, with many different clinical manifestations inside or outside of the musculoskeletal system and the skin. It is often accompanied by comorbidities like cardiovascular diseases and mental health disorders. Acute phase reactants are not always elevated and specific markers for diagnosis and/or monitor the disease are lacking thus far. These characteristics possibly reflect the difficulty in agreement about a disease activity index for PsA. Many indices have been proposed over the last years, each of them considering different combinations of disease characteristics. We performed a literature search for relevant articles using PubMed and Embase. No data limits were applied. The keywords "Psoriatic arthritis" OR "PsA" AND "disease activity" AND "index" OR "indices" were used. Reference lists of relevant articles were also reviewed. Articles were also identified through searches of the authors' own files. In this review, we comparatively present the available indices (simple or composite) used for measuring activity in PsA, highlighting their weaknesses, strengths, and disparities. We comment also on the caveats and pitfalls that are encountered in assessment of disease activity, in relation to clinical practice and research. A widely accepted index for measuring disease activity in PsA is lacking. Other parameters, mostly related to patient-reported outcomes and to novel biomarkers might be included in the future, in such indices. Key points • Disease activity in PsA is multiparametric and its assessment is challenging due to many different phenotypes. • Many different indices are currently in use of PsA disease activity assessment. • Each PsA disease activity index has specific pros and cons.
Keywords: Activity index; Disease activity; Psoriatic arthritis.
© 2021. International League of Associations for Rheumatology (ILAR).
Similar articles
-
Functional impairment measurement in psoriatic arthritis: Importance and challenges.Semin Arthritis Rheum. 2018 Dec;48(3):436-448. doi: 10.1016/j.semarthrit.2018.05.010. Epub 2018 May 23. Semin Arthritis Rheum. 2018. PMID: 30029795 Review.
-
Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial.Arthritis Care Res (Hoboken). 2020 Nov;72(11):1579-1588. doi: 10.1002/acr.24046. Arthritis Care Res (Hoboken). 2020. PMID: 31421033 Free PMC article. Clinical Trial.
-
Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set.J Rheumatol. 2019 Mar;46(3):266-273. doi: 10.3899/jrheum.180195. Epub 2018 Nov 1. J Rheumatol. 2019. PMID: 30385708
-
Evidence-based algorithm for diagnosis and assessment in psoriatic arthritis: results by Italian DElphi in psoriatic Arthritis (IDEA).Reumatismo. 2016 Dec 16;68(3):126-136. doi: 10.4081/reumatismo.2016.913. Reumatismo. 2016. PMID: 27981814
-
Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies.J Autoimmun. 2017 Jan;76:21-37. doi: 10.1016/j.jaut.2016.10.009. Epub 2016 Nov 9. J Autoimmun. 2017. PMID: 27836567 Review.
Cited by
-
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice.Ther Adv Musculoskelet Dis. 2022 Sep 5;14:1759720X221122417. doi: 10.1177/1759720X221122417. eCollection 2022. Ther Adv Musculoskelet Dis. 2022. PMID: 36081746 Free PMC article.
-
Comparison between methotrexate and apremilast in Psoriatic Arthritis-a single blind randomized controlled trial (APREMEPsA study).Rheumatol Int. 2023 May;43(5):841-848. doi: 10.1007/s00296-023-05315-4. Epub 2023 Mar 24. Rheumatol Int. 2023. PMID: 36961603 Free PMC article. Clinical Trial.
-
Serum Calprotectin as a Promising Inflammatory Biomarker in Psoriatic Arthritis: a 1-Year Longitudinal Study.Rheumatol Ther. 2023 Feb;10(1):149-160. doi: 10.1007/s40744-022-00501-5. Epub 2022 Oct 21. Rheumatol Ther. 2023. PMID: 36271188 Free PMC article.
-
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional study.RMD Open. 2022 Nov;8(2):e002626. doi: 10.1136/rmdopen-2022-002626. RMD Open. 2022. PMID: 36323487 Free PMC article.
-
"It's Like Listening to the Radio with a Little Interference": A Qualitative Study Describing Pain Management among Patients with Psoriatic Arthritis.J Clin Med. 2023 Nov 27;12(23):7348. doi: 10.3390/jcm12237348. J Clin Med. 2023. PMID: 38068399 Free PMC article.
References
-
- Ritchlin CT, Colbert RA (2017) Gladman DD Psoriatic arthritis. N Engl J Med 376:957–970. https://doi.org/10.1056/NEJMra1505557 - DOI - PubMed
-
- Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H (2006) Group CS Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 54:2665–2673. https://doi.org/10.1002/art.21972 - DOI - PubMed - PMC
-
- Feld J, Chandran V, Haroon N, Inman R (2018) Gladman D Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol 14:363–371. https://doi.org/10.1038/s41584-018-0006-8 - DOI - PubMed
-
- Perez-Chada LM (2020) Merola JF Comorbidities associated with psoriatic arthritis: review and update. Clin Immunol 214:108397. https://doi.org/10.1016/j.clim.2020.108397 - DOI - PubMed
-
- Fragoulis GE, Evangelatos G, Tentolouris N, Fragkiadaki K, Panopoulos S, Konstantonis G, Iliopoulos A, Chatzidionysiou K, Sfikakis PP (2020) Tektonidou MG Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus. Ther Adv Musculoskelet Dis 12:1759720X20976975. https://doi.org/10.1177/1759720X20976975 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous